Last reviewed · How we verify

Itraconazole capsule

Advenchen Laboratories Nanjing Ltd. · FDA-approved active Small molecule Quality 5/100

Itraconazole capsule is a Small molecule drug developed by Advenchen Laboratories Nanjing Ltd.. It is currently FDA-approved. Also known as: Itraconazole, PUR1900, azole antifungal, CYP3A4 inhibitor (perpetrator drug).

At a glance

Generic nameItraconazole capsule
Also known asItraconazole, PUR1900, azole antifungal, CYP3A4 inhibitor (perpetrator drug), Icon
SponsorAdvenchen Laboratories Nanjing Ltd.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Itraconazole capsule

What is Itraconazole capsule?

Itraconazole capsule is a Small molecule drug developed by Advenchen Laboratories Nanjing Ltd..

Who makes Itraconazole capsule?

Itraconazole capsule is developed and marketed by Advenchen Laboratories Nanjing Ltd. (see full Advenchen Laboratories Nanjing Ltd. pipeline at /company/advenchen-laboratories-nanjing-ltd).

Is Itraconazole capsule also known as anything else?

Itraconazole capsule is also known as Itraconazole, PUR1900, azole antifungal, CYP3A4 inhibitor (perpetrator drug), Icon.

What development phase is Itraconazole capsule in?

Itraconazole capsule is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing